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INTRODUCTION 
 Diarrhoeal disorders in children cause mortality and morbidity. It is still 
one of the leading killers in under 5 children. It has been estimated to cause 
nearly 8% of childhood deaths in the year 2016.  Rotavirus is considered to be 
one of the leading culprits in causing severe dehydrating gastroenteritis in the 
under 5 children. Globally it is said to account for nearly 111 million cases of 
diarrhoea annually in children under 5 year of age, and cause nearly 500000 
deaths per year(1) 
 Rotavirus infection has a very broad spectrum ranging from 
asymptomatic infection to severe dehydrating life threatening diarrhoea. WHO 
estimates suggest that about 34% of diarrhoeal deaths are due to rotavirus in 
India. About 95% of under 5 children are affected by rotavirus irrespective of 
socio-economic status.  This is due to the fact that improvement in hygiene and 
sanitation may help in reducing the burden of other gut pathogens, but plays no 
role in reducing rotaviral burden. The only possible solution to reduce this 
burden is the use of effective vaccine against rotavirus(2) 
  With recent introduction of effective rotavirus vaccines, there has been a 
decline in diarrheal deaths due to rotavirus. But it is still a major cause of 
morbidity accounting for severe dehydrating gastroenteritis requiring 
hospitalisation. Also prolonged episodes may lead to adverse outcomes in the 
 2 
 
long run like malnutrition, micronutrient deficiencies, deficits in cognitive and 
psychomotor development. Thus it poses a major burden on the health care 
system(1)  
 There has been a decline in global deaths due to diarrhoea over the past 
two decades as per recent studies. But it has also been revealed that diarrhoeal 
hospitalizations, owing to rotavirus, has been increasing(3). Some studies in the 
Asian population have revealed a two fold increase in rotaviral diarrhoeas 
requiring hospitalizations, when compared to previous studies. Indian studies in 
health care facilities have revealed that 26% of all diarrhoea related 
hospitalizations is due to rotavirus. Rotavirus exhibits an unusual genomic 
diversity in India, thus necessitating the need for continuous surveillance for 
different serotypes(4). Knowledge about the local circulating serotypes would 
help in assessing the adequacy of the current vaccines and need for new ones. 
 Previously two vaccines developed in western countries- a monovalent 
live attenuated vaccine and a pentavalent human-bovine reassortant vaccine 
were available in the market. But due to the high cost, it was out of reach for the 
vast low income population of the country. Recently an indigenous strain 
isolated from a neonate with rotavirus (116E) was developed into an oral 
monovalent vaccine(5). After extensive studies, it was licensed for use in India in 
2014. It was introduced in the UIP in a phased manner since 2016. The 116 E 
strain was introduced in Tamilnadu in the month of september 2017. This new 
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vaccine with much lower costs, is expected to reduced the burden of severe 
gastroenteritis. This will further help in reducing the burden on the health care 
system.  
 As the 116E is introduced into the UIP, it becomes essential to monitor its 
public health impact. A decline in child deaths and hospitalizations due to 
rotavirus diarrhoea is expected. Documenting these events become essential to 
health care providers to sustain the use of vaccine. If the vaccine is found to be 
unsatisfactory, need for modification of formulations or dosing schedules 
should be considered(6).  
 Although theoretically rotavirus is said to be the major cause of severe 
diarrhoea in under 5 children, the exact burden in our institute has not been 
studied previously. This study attempts to estimate the actual prevalence of 
rotaviral diarrhoea in under 5 children of the pediatric population of Madurai. It 
also aims at ascertaining the common circulating genotypes of rotavirus in this 
population. 
Another key factor to be considered is the safety of this vaccine. 
Intussusception, is considered a serious side effect of the previous 
internationally licensed rotavirus vaccines. 
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 There was no demonstrable increased risk of intussusception with the 
116E in clinical trials. But these trials were not powerful enough to detect any 
low risk. So this study was also designed to identify and monitor the 
epidemiology of pediatric intussusception cases in under 2 children(6).  
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REVIEW OF LITERATURE 
 Gastroenteritis is a term denoting gastrointestinal tract infections caused 
by various pathogens. Most of these are foodborne infections. Diarrhoea is one 
of the common manifestations of these infections. In public health settings, 
diarrhoeal disorders is the term used to denote the common infectious causes. 
EPIDEMIOLOGY: 
 One of the leading causes of childhood mortality globally is diarrhoea, 
accounting for nearly 9% of childhood deaths. The vast majority of these cases 
occur in Africa and South Asia (80% of episodes). Although there has been a 
decline in global mortality due to diarrhoea, the overall incidence hasn’t 
changed much.  Rotavirus infection is considered to be the major cause of 
severe dehydrating diarrhoea especially in young children. Rotavirus is a 
significant cause of pediatric mortality and morbidity.  
STRUCTURE: 
 Rotavirus belongs to the family of reoviridae, capable of infecting all 
mammals and birds. The virus is a RNA virus with its structure resembling a 
wheel, triple shelled icosahedrons.  It contains 11 segments of double stranded 
RNA. Its diameter is about 80 nm when seen through an electron microscope. 
They are classified into 7 serogroups – A, B, C, D, E, F, and G. They are also 
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classified into 2 subgroups – I or II. These strains are usually species specific. 
They do not infect heterologous hosts. Human infections are usually caused by 
group A virus. Group B can infect infants in the Chinese population. Group C 
virus is said to cause occasional human outbreaks. The other serotypes do not 
usually infect humans(1). 
 The virus has six structural proteins namely VP1, VP2, VP3, VP4, VP6 
and VP7. Infective strains of rotavirus have additional non structural proteins, 
namely NSP1, NSP2, NSP3, NSP4, NSP5, and NSP6. The antigenic structure of 
the inner capsid protein, VP6 determines the subgroup of rotaviruses. Group A 
viruses are further classed into serotypes which is determined by classic cross-
neutralization testing and depends on the outer capsid glycoproteins VP7 & 
VP4. VP7 serotype is referred to as G type (glycoprotein). There are 19 G 
genotypes (14 serotypes) out of which 4 more commonly infect humans. VP4 
serotype is referred to as the P type and determines the virulence of the infecting 
strain. There are a total of 27 P genotypes (14 serotypes). There exists varying 
combinations of G and P types between strains and a binomial naming system is 
hence used to identify the strains. Both VP7 and VP4 induce neutralizing IgG 
antibodies. But their protective role remains unclear, whereas mucosal IgA 
antibodies have a protective role. 
 Currently, in the global scenario, five G-P combinations (G1P[8], 
G2P[4], G3P[8], G4P[8]) and G9P[8]) cause approximately 90% of all human 
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rotavirus infections and among them, type G1P[8] is found to be the most 
prevalent one. In India, the common serotypes are G1P[8], G2P[4], G9P[8], and 
G9P[4]. Many other serotypes have also been detected. Within a given 
geographical area, the prevailing types may differ considerably from one season 
to the next(7). 
 
 
 
 8 
 
The estimated burden of rotavirus diarrhoea globally in under 5 children 
is 111 million cases. About 18 million cases of these are considered to be severe 
diarrhoea. Rotavirus causes about 500000 deaths per year. In India it is 
estimated to cause 11.3 million illnesses, 3.27 million OP visits. They are 
responsible for 8.7 million inpatient admissions every year, accounting for 
about 10 billion of the health care expenses. The mortality rate estimated is 
about 78000 deaths annually(7).  
 Rajiv Bhal et al in the year 2005 conducted a study where 62,475 
children <5 years of age were included in the study population, with 
approximately equal numbers of children in each 1-year age group up to 5 years 
of age. A total of 584 children from study households who were hospitalized 
with diarrhea were identified during the surveillance period of a year. Of these 
584 children, 137 (23.5%) had a stool specimen that tested positive for 
rotavirus, yielding an incidence of rotavirus diarrhea-associated hospitalization 
of 337 hospitalizations/100,000 children <5 years of age. This study indicates 
that ∼1 in 59 children in the Indian population is likely to be hospitalized with 
rotavirus diarrhea between birth and 5 years of age(4). 
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Rotavirus infection is most common in winter months in temperate 
climates. Unlike other viruses, the increased seasonal spike is not caused by a 
single strain or serotype. The disease is more severe in children under 2 years of 
age. 25% of severe cases occur in children more than 2 years of age. Serologic 
evidence of infection occurs in almost all children by 5 years of age. Infants 
upto 3 months are protected by breastfeeding and transplacental antibodies. 
Thus infections in neonates and adults are generally asymptomatic, and often go 
unnoticed(1).  
 Rotavirus spreads and causes infection through fecal-oral route, with 
outbreaks occurring in health care and day care centres. The viral load shed in 
stools is very high in the order of 1011, while the infective dose is relatively low 
in the order of 103. Thus very few infectious virions can cause disease in a 
susceptible host.  
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PATHOGENESIS: 
 Rotavirus causes enteritis by selectively infecting and destroying villus 
tip cells in the small intestine. Varying degrees of villus blunting and round cell 
infiltrate in the lamina propria has been noticed in biopsy specimens of small 
intestine. The severity of disease may not correlate with the pathologic changes, 
and these changes usually resolve much before clinical resolution. Despite the 
use of the term gastroenteritis, gastric mucosa is not affected usually(1).  
The villus enterocytes of small intestine are well differentiated cells with 
digestive and absorptive functions. The digestive functions include hydrolysis 
of disaccharides, while the absorptive functions include the transport of water 
and electrolytes through glucose and amino acid cotransporters. The crypt 
enterocytes are secretors of water and electrolytes, but lack the brush border 
hydrolytic enzymes. The non-structural protein NSP4 has been found to be an 
enterotoxin in the pathogenesis. Altered absorption is the major factor 
contributing to diarrhoea. Infection of the villus cells leads to 
1. Imbalance in the ratio of intestinal fluid absorption to secretion due to 
decreased absorption of salt and water. 
2. Malabsorption of complex carbohydrates especially lactose, due to 
decreased disaccharidase activity.  
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Viremia might occur in severe infections, but doesn’t usually cause 
symptoms in immunocompetent individuals. Hepatic and renal involvement 
may be noted in immunocompromised patients. The occurrence of viral enteritis 
increases intestinal permeability to macromolecules in the lumen, causing 
increased risk of food allergies. 
The following factors contribute to the increased vulnerability of infants 
leading to increased morbidity and mortality: 
1. Decreased reserve function of the intestine 
2. Lack of specific immunity 
3. Decreased gastric acid and mucus which are non specific host defence 
mechanisms.  
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CLINICAL FEATURES: 
 Rotavirus infection begins after an incubation period of 48 hours (ranges 
from 1-7 days). It begins with the onset of mild to moderate fever and vomiting 
followed by the occurrence of frequent, watery stools. About 50-60% cases 
present with all 3 symptoms. Vomiting and fever usually subside by the 2nd day, 
but diarrhoea continues for 5-7 days. Stool doesn’t show WBC or blood. Severe 
dehydration may ensue rapidly especially in infants and it progresses rapidly 
unless treated early. Most severe disease usually occurs in the age group of 4-36 
months of age(1).  
Children with intestinal disease such as short bowel syndrome and 
malnourished children suffer from severe and prolonged illness. Affected 
newborns are usually asymptomatic due to maternal protection (breastfeeding & 
transplacental antibodies). A few reports of occurrence of necrotising 
enterocolitis have been reported with new strains. 
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DIAGNOSIS: 
 Clinical and epidemiological features are sufficient in most cases to make 
a satisfactory diagnosis. Enzyme linked immunosorbent assays show sensitivity 
and specificity of >90% can detect group A rotavirus in stool samples. Latex 
agglutination kits are also available for group A virus, but they are found to be 
less sensitive than ELISA. 
 Other techniques available are electron microscopy, RNA polymerase 
chain reaction analysis to identify serotypes based on G and P antigens.  
 Other corroborative findings are dehydration with acidosis seen in severe 
viral enteritis. Stools are free from blood and leucocytes. The WBC count may 
be moderately elevated, but significant left shift is absent unlike bacterial 
enteritis. 
DIFFERENTIAL DIAGNOSIS: 
MEDICAL: bacterial and protozoal enteritis 
SURGICAL: appendicitis, bowel obstruction, intussusception. 
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TREATMENT: 
 The major goals of treatment are avoiding and treating dehydration, and 
maintaining the nutritional status of the patient.  
 There has been no demonstrable role for antivirals. Similarly no proven 
benefit has been shown from the use of anti-emetics or anti-diarrhoeal drugs. 
On the other hand these drugs increase the risk of serious side effects, hence 
avoided. The use of probiotics like Lactobacillus species may help in mild 
cases, but not in severe dehydrating cases. Experimental treatment includes the 
use of immunoglobulins orally in patients with severe rotavirus gastroenteritis. 
 
PRINCIPLES OF TREATMENT(8): 
 General assessment 
 Assessing the hydration status. There are a number of clinical symptoms 
and signs that help in detecting dehydration. The following table includes 
few reliable clinical signs that help in quick assessment of the level of 
dehydration.  
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GENERAL 
CONDITION(8) 
 alert irritable Lethargic, 
comatose 
EYES Normal Sunken Sunken 
THIRST Drinks normally Drinks eagerly Drinks poorly, 
unable to drink 
SKIN PINCH Goes back 
normally 
Goes back 
slowly 
Goes back very 
slowly 
HYDRATION 
STATUS 
No dehydration 2 or more of the 
above signs 
indicate SOME 
dehydration 
2 or more of the 
above signs 
indicate 
SEVERE 
dehydration 
TREATMENT 
PLAN 
Plan A Plan B Plan C 
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 Correct electrolyte and acid base disturbance if any 
 Adequate feeding to provide normal nutrition 
 Zinc supplementation 
 Nutritional rehabilitation 
 Health education to prevent diarrhoea 
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ORAL REHYDRATION THERAPY(8): 
 It is the most cost effective and efficient treatment option. It is based on 
the principle of coupled active transport of glucose and sodium in the small 
bowel, resulting in passive absorption of water and electrolytes during copious 
diarrhoea. ORT includes: 
- WHO low osmolar ORS solution 
- Home made sugar and salt solution 
- Food based solutions like lentil soup, rice water, porridge, butter milk 
Low osmolarity ORS: 
 Conventional ORS with a higher osmolarity was a life saver but did not 
decrease the duration or frequency of diarrhoea. The current recommendation is 
low osmolar ORS for all ages and all causes of diarrhoea(8): 
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TREATMENT OF DEHYDRATION: 
MANAGEMENT OF NO DEHYDRATION(8): 
 Aims at preventing dehydration and malnutrition. This can be carried out 
at home by mother/caregiver who is given the following advice: 
- Give excess fluids than normal 
- Continue oral feeding 
- Advise followup after 2 days or earlier if the child shows any danger 
signs like – thirsty, irritable/restless, fever, persistent vomiting, high 
purge rate, blood in stool, lethargic, eats/drinks poorly 
The guidelines for treating children with NO DEHYDRATION(8) (PLAN A) 
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MANAGEMENT OF SOME DEHYDRATION: 
 This aims at treating dehydration, electrolyte imbalance and continue oral 
feeding. Children are treated at in a health care facility with ORS under 
supervision (PLAN B) (8): 
- Deficit correction: 50-100ml/kg (75ml/kg) of ORS must be administered 
over 4 hours. Child can be given more ORS, if the child wants more. 
Breastfeeding should be continued. 
- Older children should also be given plain water on demand 
- Close monitoring of ORS acceptance, purge rate and vomiting should be 
done 
Reassessment after 4 hours: 
- If child appears still dehydrated, deficit therapy is repeated (PLAN B) 
- If rehydrated, switch over to PLAN A – no dehydration 
- If ORT is not successful, switch to PLAN C – severe dehydration with IV 
fluids. 
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MANAGEMENT OF SEVERE DEHYDRATION: 
Aims at quickly rehydrating the child in a health care facility by giving 
IV fluid therapy. The preferred solution is Ringer’s lactate for rehydration. If 
Ringer’s lactate is not available, normal saline may be used. 
DEFICIT THERAPY FOR SEVERE DEHYDRATION – PLAN C(8) 
 
ZINC SUPPLEMENTATION: 
 Zinc deficiency is common in Indian children owing to the diet. IAP 
recommends that children older than 6 months should receive elemental zinc 
20mg for 14 days. Children between 2-6 months of age should receive 
elemental zinc 10mg for 14 days. 
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PROGNOSIS: 
 Morbidity and mortality occurs due to dehydration and delayed access to 
health care facility. With each subsequent natural infection, severity of the 
illness decreases. Primary infection induces only serotypic specific antibody. 
But reinfection induces a broad response cross reactive heterotypic antibody. 
After the initial natural infection, protection is high against moderate and severe 
infection but there is not much protection against asymptomatic infection. But 
with subsequent infections, protection is offered against asymptomatic, mild 
and severe illness(1). 
PREVENTION: 
Good hygiene and handwashing doesn’t help much in preventing 
rotavirus infection. Handwashing and isolation nursing might help in preventing 
noscomial outbreaks. Vaccines are the best hope in preventing rotavirus 
infections 
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VACCINES: 
Initially a trivalent rotavirus vaccine was licensed in the United States, 
which was subsequently linked to high risk of intusussception. The vaccine was 
withdrawn subsequently from the market.  
In the western countries two vaccines were tested and licensed later. They 
have been in use for the past 2 decades. But due to its high cost, they are out of 
reach for the poor underprivileged children of our nation.  
In the year 1988, a naturally occurring attenuated human-bovine 
reassortant strain of rotavirus was isolated from an asymptomatic neonate at the 
All India Institute of Medical Sciences. Later with international support, the 
strain 116E was used to develop a monovalent oral vaccine. Early trials showed 
the vaccine to be effective and well tolerated among 4,532 Indian infants, with 
efficacy against severe disease being 53.6%(9). Following which the 116E 
vaccine was licensed for use in India in 2014 at an estimated cost of under 
rupees 70 per dose. This vaccine proves a more suitable alternative than the 
western vaccines (rupees 1000 per dose). In July 2014, an announcement was 
made to introduce the 116E vaccine to India’s Universal Immunization 
Programme (UIP). The rollout of the new vaccine in India’s UIP begin in the 
year 2016 in a phased manner. Initially it was introduced in 4 states namely 
Haryana, Andhra Pradesh, Odisha, Himachal Pradesh(7). In the year 2017 the 
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programme was extended to 5 more states Tamilnadu, Madhya Pradesh The 
vaccine administration in Tamilnadu was initiated in September 2017. 
Johnie Rose et al conducted a study in 2016 where a dynamic simulation 
model was used to compare the coverage with 116E strain against no 
vaccination in India. An established 116E vaccination program was estimated to 
reduce symptomatic rotavirus infection by 13.0%, while reducing mortality by 
34.6% (over 34,000 lives annually). Rotavirus outpatient visits was estimated to 
decline by 21.3%, and hospitalization by 28.1%. The cost reduction estimate per 
disability-adjusted life year (DALY) was 3,429 Rupees. The study also 
predicted that the mortality reduction in children born during the first five years 
of vaccination implementation would be nearly identical to that in children born 
in later years (34.4% versus 34.6%)(5). 
The 116E vaccine is said to have an efficacy of 40-60% in preventing 
severe & life threatening diarrhoea. As per WHO 2013 analysis, it is said to 
offer herd protection in older children & adults.  It is administered in the 
Universal Immunisation Programme at 6, 10 & 14 weeks along with pentavalent 
vaccine and OPV.  
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STRAIN ORV 116E RV1 G1P8 RV5 G1,G2,G3, 
G4, P1A8 
VALENCY Monovalent Monovalent Pentavalent 
DOSAGE 6, 10 & 14 weeks 2  & 4 weeks 2, 4 & 6 weeks 
INTRODUCTION 2013 2008 2006 
COST PER DOSE 
(IN RUPEES) 
68 900 1000 
 
CONTRAINDICATIONS: 
- Known allergy to vaccine 
- Previous history of intussusception/ abdominal surgery/ intestinal 
malformation 
- Known immunodeficiency 
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PROTECTION: 
 The vaccine offers protection upto 2 years, beyond which natural 
immunity is well developed 
ADVERSE EFFECTS: 
1. Minor & common side effects include diarrhoea, vomiting, cough, 
running nose, fever, rash, irritability 
2. Acute gastroenteritis in approximately 1 in 600 infants 
3. Anaphylaxis – further doses should be withheld 
4. Intussusception  
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INTUSSUSCEPTION AND NEED FOR SURVEILLANCE: 
 Intussusception is defined as the invagination of one segment of bowel 
into a distal segment. The part of bowel that invaginates is called 
intussusceptum. The part of bowel that receives it is called intussuscipiens. 
The most common site involved is Ileocolic part of the bowel. 
When one part of bowel invaginates into another, the blood vessels 
supplying the intestine get squeezed between these two portions. This leads 
to kinking and compression of the vessels. This in turn leads to venous 
stasis, congestion and edema of the intestine. This causes outpouring of 
mucus and blood into the bowel lumen. This lead to the characteristic red 
currant jelly stools of intussusception. 
 
 
Bowel 
invagination
compression of 
blood vessels
stasis, 
congestion, 
edema
outpour of 
mucus & blood
RED CURRANT 
JELLY STOOLS
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 It results in ischemia, gangrene, perforation within 72 hours. Affected 
children may succumb to the illness within 5 days if unrelated. The 
incidence in male:female population is 2:1 to 3:2. Majority of cases occur in 
children less than 1 year, with peak of incidence occuring from 3 to 6 
months of age. 75% of cases occur in the first 2 years of life, with about 90% 
occurring in the first 3 months of life. 
TYPES: 
Based on resolution: 
A) Permanent 80%  
B) Transient 20% 
Based on etiology: 
a) No lead point 95%: 
May be due to inflammation of peyer’s patches. Ingestion of cows 
milk has more risk. Malnourished children have fewer lymphoid tissue 
hence have less risk. 
b) Pathological lead point 4%: 
Ileoileocolic, inverted meckels diverticulum, polyps, duplication, 
tumours, trauma may act as lead points 
c) Post operative 1%: small bowel obstruction. 
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Based on site: 
a) Ileocolic 85% 
b) Ileoileocolic 10% 
c) Others: 5% cecocolic, colocolic, appendicocolic 
 
CLINICAL FEATURES: 
Vomiting 
Abdominal pain – colicky pain, child may cry with pulled up legs 
Abdominal mass – sausage shaped mass may be felt. Dance sign – retraction in 
right iliac fossa. 
Rectal bleeding – last symptom to occur- red currant jelly stool 
 
DIAGNOSIS: 
X RAY: meniscus sign , target sign 
USG abdomen: target/doughnut sign on cross section 
Pseudokidney sign on longitudinal section 
Detects lead point in 66% of cases 
CT/MRI 
CONTRAST ENEMA 
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TREATMENT: 
MEDICAL:  
  Steroids may be tried in some cases like those associated with Henoch 
Schonlein Purpura 
RADIOLOGICAL REDUCTION: 
 Pneumatic 
 Hydrostatic 
Under fluoroscopic/ USG guidance 
Contraindicated in shock, perforation, peritonitis, dehydration. 
 
COMPLICATIONS OF SURGERY: 
 Perforation 
 Wound infection 
 Small bowel obstruction 
 Fascial dehisence 
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In the year 1999, a first generation trivalent oral rotavirus vaccine, was 
withdrawn from the US market because of an increased risk of intussusception 
occurring after its administration. 1 case of intussusception per 10,000 vaccine 
recipients was the population attributable risk estimated. Highest risk (>30-fold) 
was observed within 1 week of the administration of the first dose of the 
vaccine. This temporal association between the vaccine and intussusception was 
unexpected, and led to the withdrawal of the vaccine. Public health efforts were 
delayed to reduce the burden of rotavirus worldwide. Large pre-licensure trials 
were needed to demonstrate the safety of the rotavirus vaccines introduced 
thereafter. 
   With increasing awareness regarding intussusception, pre-clinical safety 
trials became mandatory for the current World Health Organization (WHO) pre-
qualified monovalent and pentavalent rotavirus vaccines. A study was done 
among >60,000 infants and identified no vaccine attributable intussusception 
risk.  The exact physiological reason causing the association of rotavirus 
vaccines and intussusception is not well understood. 
 Data regarding intussusception associated hospitalizations is not available 
in developing countries including India. Hence surveillance and assessment of 
baseline data regarding intussusception related hospitalizations is the need of 
the hour to ensure safety of the the 116E vaccine. This will help the policy 
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makers to assess the safety of the vaccine and implement any changes in dosage 
or schedule if needed(6). 
 Gagandeep kang et al in the year 2015 published a trial that included 
6800 children out of which 4532 children received rotavirus 116E strain while 
the rest were given placebo. The study found that the children who received 
placebo had 53% more chance of developing gastroenteritis. Also the study 
showed that 17 out of the vaccine group developed intussusception, while 6 
among the placebo group developed intussusception. The natural occurrence of 
intussusception is 1 in 20,000 cases. Hence this trial did not have sufficient 
power to detect the safety of the vaccine with respect to intussusception(9). 
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AIMS AND OBJECTIVES 
1. To estimate the prevalence of rotaviral diarrhoea among children less 
than 5 years of age hospitalised for acute gastroenteritis. 
2. To determine the common circulating genotypes of rotavirus in the 
given geographical region 
3. To compare the prevalence and common genotypes of rotavirus in 
children vaccinated for rotavirus against unvaccinated children 
4. To describe the epidemiology of intussusception cases under 2 years 
of age, admitted at GRH, Madurai. 
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MATERIALS AND METHODS 
 This study was a prospective analytical hospital based study conducted in 
children aged less than 5 years admitted with gastroenteritis to the Institute of 
Child Health & Research Centre (ICH&RC), Government Rajaji Hospital, 
Madurai. The study was conducted over a period of one year (September 2017 – 
August 2018). Also included were children less than 2 years of age admitted 
with a diagnosis of intussusception. 
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INCLUSION CRITERIA & CASE DEFINITION: 
- A case of acute gastroenteritis is defined as the passage of more than or 
equal to three loose or watery stools over a period of 24 hours. 
- Children less than 5 years of age 
EXCLUSION CRITERIA: 
- Children > 5 years of age 
- Children with chronic or persistent diarrhoea (lasting >14 days) 
- Children with acute dysentery   
- Children whose parents failed to give informed consent 
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INTUSSUSCEPTION SURVEILLANCE: 
INCLUSION CRITERIA: 
- Children below 2 years of age 
-  The case definition of intussuception was done as per the modified 
Brighton criteria(10) 
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- Institutional ethical committee was obtained 
- After getting informed parental consent, all children under 5 years of 
age admitted to the hospital were enrolled in the study.  
- Basic information regarding the demographics were obtained. 
- Vaccination details were obtained from the vaccination card 
- History regarding the onset and duration of symptoms like onset, 
frequency, duration of loose stools, vomiting, fever, urine output were 
obtained meticulously from the caregivers. 
- A thorough examination was done, the level of dehydration was 
assessed based on IMCI guidelines and documented. 
- Anthropometry of the children were documented 
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SAMPLE COLLECTION: 
- The caregivers were given a container with a spatula to collect stool 
sample and asked to collect about 5-10 ml of stool in it. A marking was 
made to ensure the appropriate level for collection on the container. And 
the following instructions were given to the caregivers. 
-  The patient was placed on a plastic sheet. Stool was scooped from the 
plastic sheet with a wooden spatula and poured into the stool container 
until the mark was reached. 
- The container was screwed tightly with the cap.  
STORAGE & TRANSPORT: 
- Ensuring universal precautions, the container was labelled with the 
patient details and ID then stored in the freezer compartment of the 
refrigerator (at -20ºC) 
- Later the stored sample containers were transported to a reference 
laboratory in vaccine carrier with frozen ice packs ensuring maintenance 
of cold chain. 
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SAMPLE ANALYSIS: 
- In the reference laboratory, the stool samples were analysed as follows: 
- The first step in analysis was Enzyme Linked Immuno Sorbent Assay 
(ELISA)  
- Initially the sample containing rotavirus was added to a well containing 
anti-rotavirus antibodies 
- Now the rotavirus antigens were captured by the antibody 
- Then the sample was washed thrice to discard unbound antigen 
- Then an enzyme-conjugated rotavirus antibody was added to the well. 
- The sample was again washed thrice to discard excess unbound antigen 
- Now the specific anti-rotavirus enzyme conjugate binds to captured 
rotavirus antigens. 
- Then the sample was incubated at 39ºC. 
- A coloured product if formed indicating the presence of rotaviral 
antigens. 
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IDENTIFICATION OF SEROTYPES: 
 Once a sample was found to be positive for the presence of rotaviral 
antigens on ELISA, a Polymerase Chain Reaction (PCR) test is done. 
This helped in detecting the structural proteins on the surface of the virus 
namely G and P serotypes, thereby helping in identifying the strain of the 
infecting serotype 
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Stool sample collected and stored at 
-20ºC, sent to referral laboratory
ELISA testing done on stool sample 
to detect rotavirus antigen
If ELISA is found to be positive, PCR 
is done to identify the G & P 
serotypes of the infecting strain
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INTUSSUSCEPTION SURVEILLANCE: 
 After obtaining informed parental consent, all children under 2 years of 
age hospitalized for intussusceptions were enrolled in the study 
 The diagnosis of intussusception was made based on Modified Brighton 
Criteria(10) as follows: 
Level 1 of diagnosis (or “definite”):  
 Surgical criteria: 
o Demonstrating intestinal invagination at surgery; and/or 
 Radiological criteria: 
o Demonstrating intestinal invagination  by  air or liquid 
contrast enema; or 
o Demonstrating an intra-abdominal mass by ultrasound of 
abdomen with specific characteristic features namely - target 
sign or doughnut sign on transverse section and a 
pseudokidney or sandwich sign on longitudinal section,  and 
that which is proven to be reduced by hydrostatic enema on 
an ultrasound done ; and/or 
 Autopsy criteria: 
o Demonstrating intestinal invagination at autopsy 
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- History regarding the onset, duration of symptoms like fever, abdominal 
pain, vomiting, bloody stools, are obtained. 
- Vaccination history was elicited meticulously especially with regard to 
rotavirus vaccination 
- The mode of treatment including spontaneous resolution, surgical 
reduction or resection anastomosis were recorded. 
- Caregivers were given containers to collect stool samples, they were 
instructed as mentioned above 
- Once adequate stool sample was collected, it is stored at -20ºC in the 
freezer compartment of refrigerator 
- Then the samples were shipped to the reference laboratory in freezer box 
ensuring adequate cold chain. 
- The stool samples were analysed with ELISA as mentioned above to 
detect rotaviral antigens.  
- The stool samples found to be positive for rotavirus antigens, were 
subjected to PCR to detect serotypes of the infecting strain. 
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STATISTICAL ANALYSIS: 
 Collected data was entered into Microsoft excel sheet. Statistical analysis 
was done using SPSS software (IBM, USA). Mean and standard deviation were 
used to report data. Comparison of results between vaccinated and unvaccinated 
group was done using chi square test. A P value of <0.05 was considered to be 
statistically significant. 
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OBSERVATION AND RESULTS 
 During the study period of one year, a total of 180 cases of acute 
gastroenteritis were included in our study. This included cases admitted in the 
wards and the cases treated at casualty on day care basis. Also 10 cases of 
intussusception admitted to the pediatric surgery ward were studied. The results 
are as follows: 
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AGE DISTRIBUTION 
AGE 
DISTRIBUTION 
(months) 
NO OF 
CASES 
PERCENTAGE 
<12  137 76.1 
13-24  31 17.2 
25-36  7 3.9 
37-48  5 2.8 
49-60  0 0.0 
TOTAL 180 100.0 
Mean: 12.04 months 
Standard deviation – 9.07 
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GENDER DISTRIBUTION 
 
SEX NO.OF CASES PERCENTAGE 
 
 
Male 104 57.8 
 
 
Female 76 42.2 
 
 
Total 180 100 
 
 
 
 
 
 
58%
42%
GENDER DISTRIBUTION
Male Female
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SEVERITY OF ILLNESS 
 
LEVEL OF 
DEHYDRATION NO.OF CASES PERCENTAGE 
 
 
AGE WITH NO 
DEHYDRATION 106 58.9 
 
 
AGE WITH SOME 
DEHYDRATION 61 33.9 
 
 
AGE WITH SEVERE 
DEHYDRATION 13 7.2 
 
 
  180 100 
 
 
 
58.9
33.9
7.2
SEVERITY
AGE WITH NO DEHYDRATION
AGE WITH SOME DEHYDRATION
AGE WITH SEVERE DEHYDRATION
 51 
 
VACCINATION STATUS: 
 
ROTAVIRUS 
VACCINATION 
NO. OF 
CASES 
PERCENTAGE 
 
 
YES 76 42.2 
 
 
NO 104 57.7 
 
 
Total 180 100 
 
 
 
 
 
 
ROTAVIRUS VACCINE
YES
NO
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TYPE OF VACCINE RECEIVED: 
TYPE OF VACCINE PERCENTAGE 
OTHERS 1.2 
116E STRAIN 29.2 
Total 30.6 
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PARTIAL VS. COMPLETE VACCINATION: 
VACCINATION  FREQUENCY PERCENTAGE 
PARTIAL 76 42.2 
COMPLETE 44 24.4 
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STOOL ELISA: 
STOOL ELISA 
FOR ROTAVIRUS 
NO.OF 
CASES 
PERCENTAGE 
POSITIVE 58 32.2 
NEGATIVE 122 67.8 
Total 180 100 
 
 
 
 
32.2
67.8
ROTAVIRUS INFECTION
POSITIVE NEGATIVE
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GENOTYPES: 
GENOTYPES No.of cases Percentage 
G1 P8 8 14.04 
G1 P6 2 3.51 
G12 P8 5 8.77 
G3 P8 25 43.86 
G3 P4 1 1.75 
G3+G10 P8 3 5.26 
G3+G12 P8 9 15.79 
G3+G9 p8 1 1.75 
G9 P4 1 1.75 
G3P6+P8 1 1.75 
UT 1 1.75 
Total 57 100.00 
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AGE DISTRIBUTION OF INFECTED CASES 
  
AGE DISTRIBUTION 
OF ROTAVIRUS 
INFECTED CASES 
NO.OF 
CASES 
PERCENTAGE 
  
 < 12   34 58.6 
  
 13 - 24  20 34.5 
  
 25 - 36  2 3.4 
  
 36 - 48 2 3.4 
  
Total 58 100.0 
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SEVERITY AMONG INFECTED CASES 
 
SEVERITY AMONG 
INFECTED CASES 
NO.OF CASES PERCENTAGE 
AGE WITH NO 
DEHYDRATION 26 44.8 
AGE WITH SOME 
DEHYDRATION 26 44.8 
AGE WITH SEVERE 
DEHYDRATION 6 10.3 
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COMPARISON OF STOOL ELISA POSITIVITY IN VACCINATED VS.  
UNVACCINATED GROUPS 
 
  
 
 
P VALUE: 0.035 – SIGNIFICANT (<0.05) 
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POSITIVITY 
NO.OF CASES TOTAL 
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VACCINATED 6 38 44 
UNVACCINATED 52 84 136 
Total 58 122 180 
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SAMPLE SIZE n=180
ELISA POSITIVE FOR VP6 
ROTAVIRUS ANTIGEN =  58
GENOTYPING DONE FOR 
57 CASES
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A total of 180 cases of diarrhoeal children were included in the 
study(n=180). Out of which males constituted 58% while females contributed 
42%. The mean age of presentation was 12 months with a standard deviation of 
9 months. Nearly 76% of children were under 1 year of age while 17% were 
between 1-2 years of age. Majority of the cases presented with no signs of 
dehydration 59% followed by some dehydration 34% and severe dehydration 
7%. Only 5% cases had received ORT prior to hospitalization. 
 Out of the 180 children, 42% had received rotavirus vaccination (partial 
& complete) while 58% had not received vaccine. Out of this only 24% had 
received complete vaccination. Majority of the vaccinated children (73) had 
received the 116E strain used in the UIP of India while 3 Children received 
other vaccines from the private sector. 
 Stool testing by ELISA for VP6 antigen was done for 180 cases. It 
revealed a positivity of 32.2%. The positive samples were then subjected to 
PCR for genotyping. It was done for 57 out of the ELISA positive 58 cases. The 
common G-P genotypes found were G3P8 43% G3+G12P8 15.7%, G1P8 14%, 
G12P8 8.7%, G3+G10P8 5%, G9P4, G3P4, G3+G9P8, G3P6+P8, untypable 
1.7% each. 
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 The majority of children infected with rotavirus were <12 months of age 
(58%). 45% of infected cases presented with some signs of dehydration, 45% 
with no signs of dehydration while only 10% presented with severe dehydration. 
A comparison was done between stool ELISA positivity for the presence 
of rotavirus between the vaccinated (complete) and unvaccinated groups. 
Among the total study population (n=180), the complete vaccinated group 
included 44 cases, while the unvaccinated group included 136 cases.  
 Among the vaccinated group, 6 samples were positive for the presence of 
rotavirus in stool while the unvaccinated group showed 52 samples with stool 
positivity. Chi square test was applied to test if there was a statistical 
significance between the 2 groups. A P value of 0.035 was obtained which 
showed a statistical significance between the two groups. 
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INTUSSUSCEPTION SURVEILLANCE: 
AGE DISTRIBUTION: 
 
 
 
 
 
 
 
 
 
 
 
 
 
AGE DISTRIBUTION
0-12 M
13-24 M
10%
AGE IN 
MONTHS 
FREQUENCY PERCENTAGE 
0-12 9 90% 
13-24 1 10% 
90% 
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GENDER DISTRIBUTION: 
 
GENDER FREQUENCY PERCENTAGE 
MALE 6 60% 
FEMALE 4 40% 
 
 
 
 
 
 
 
60%
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VACCINATION STATUS: 
VACCINATION 
STATUS 
FREQUENCY PERCENTAGE 
COMPLETE 2 20% 
PARTIAL 2 20% 
UNVACCINATED 6 60% 
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60%
20%
20%
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MODE OF TREATMENT: 
MODE OF 
TREATMENT 
FREQUENCY PERCENTAGE 
SPONTANEOUS 
RESOLUTION 
1 10% 
PNEUMATIC 
REDUCTION 
0 0 
SURGICAL 
REDUCTION 
9 90% 
 
 
 
 
 
 
 
TREATMENT
SPONTANEOUS RESOLUTION
SURGICAL REDUCTION
90%
10%
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OUTCOME: 
OUTCOME FREQUENCY PERCENTAGE 
RECOVERED 9 90% 
DIED 1 10% 
 
 
 
 
 
 
 
 
OUTCOME
RECOVERED
DIED
90%
10%
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 A total of 10 cases of intussusception admitted to the pediatric surgery 
ward were studied. Children under the age of 2 years were included in the study. 
Out of the 10 cases, 9 were under 1 year of age (90%), about 50% were under 
the age of 6 months. The mean age of onset was 7.4 months. 60% were males 
and 40% were females. 9 cases needed surgical reduction while one case 
resolved spontaneously. Nine cases recovered well while one case had post 
operative complications and died.  
Out of the 10 cases, 4 (40%) had received rotavirus vaccination, out of 
which only 2 (20%) had received the complete series of 3 doses. The mean 
duration between the first dose of vaccine and the onset of symptoms was 42.75 
days 
 All the 10 children were tested for rotavirus antigen in their stool samples 
by ELISA technique. Only 1 sample was found to be positive for VP6 antigen 
by ELISA. But this child had not received the rotavirus vaccine. 
 Thus no causal relation can be established between the vaccine virus and 
the occurrence of intussusception. To test the safety of the vaccine all children 
receiving vaccination in the community should be monitored for the occurrence 
of intussusception. Causal association cant be established based on this small 
sample size of intussusceptions cases who presented to our hospital 
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DISCUSSION 
 Acute diarrhoeal disease is still considered a major killer illness in the 
pediatric population. It is found to be the second major cause of mortality in 
under 5 children. Apart from mortality it causes morbidity like undernutrition, 
growth retardation. Rotavirus is considered to be the major infecting agent 
causing diarrhoea in under 5 children. It adds to the burden of the health care 
system by being responsible for million of outpatient cases, inpatient 
admissions and 78000 deaths annually. 
 Vaccines for diarrhoea have been rampant in the western population for 
the past 2 decades. Their use in India is limited due to its high cost which 
precluded its use in the public health sector. A major breakthrough was the 
introduction of an indigenous vaccine strain 116E strain isolated from an Indian 
neonate. It was licensed in the year 2014. It was launched into the UIP in the 
year 2016. It was introduced in a phased manner. It was launched in Tamilnadu 
in the September 2017. 
 Safety of this vaccine was tested well in the prelicensure trials. But the 
power was not sufficient enough to test its safety with regard to intussusception. 
This study was designed to identify the burden of rotaviral illness in under 5 
children attending our hospital, to assess the impact of the recently introduced 
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vaccine and to establish a baseline surveillance of the intussuseption cases 
admitted to our hospital in children under 2 years of age. 
A total of 180 cases of diarrhoeal children were included in the 
study(n=180). Out of which males constituted 58% while females contributed 
42%. The mean age of presentation was 12 months with a standard deviation of 
9 months. Nearly 76% of children were under 1 year of age while 17% were 
between 1-2 years of age. Majority of the cases presented with no signs of 
dehydration 59% followed by some dehydration 34% and severe dehydration 
7%. Only 5% cases had received ORT prior to hospitalization. 
 Out of the 180 children, 42% had received rotavirus vaccination (partial 
& complete) while 58% had not received vaccine. Out of this only 24% had 
received complete vaccination. Majority of the vaccinated children (73) had 
received the 116E strain used in the UIP of India while 3 Children received 
other vaccines from the private sector. 
 Stool testing by ELISA for VP6 antigen was done for 180 cases. It 
revealed a positivity of 32.2%. The positive samples were then subjected to 
PCR for genotyping. It was done for 57 out of the ELISA positive 58 cases. The 
common G-P genotypes found were G3P8 43% G3+G12P8 15.7%, G1P8 14%, 
G12P8 8.7%, G3+G10P8 5%, G9P4, G3P4, G3+G9P8, G3P6+P8, untypable 
1.7% each. 
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The majority of children infected with rotavirus were <12 months of 
age(58%). 45% of infected cases presented with some signs of dehydration, 
45% with no signs of dehydration while only 10% presented with severe 
dehydration. 
A comparison was done between stool ELISA positivity for the presence 
of rotavirus between the vaccinated (complete) and unvaccinated groups. 
Among the total study population (n=180), the complete vaccinated group 
included 44 cases, while the unvaccinated group included 136 cases.  
 Among the vaccinated group, 6 samples were positive for the presence of 
rotavirus in stool while the unvaccinated group showed 52 samples with stool 
positivity. Chi square test was applied to test if there was a statistical 
significance between the 2 groups. A P value of 0.035 was obtained which 
showed a statistical significance between the two groups. 
 
Saravanan et al in the year 2003 studied the epidemiology of rotavirus in 
South Indian population. The prevalence of infection was found to be 22% 
which is much similar to our study. The common genotypes isolated were 
G2P4P8, G1G2P4P8, G1P4, G2P8, G4P4, G10P11, G9P11, G9P6 which is 
much different from the prevalent genotypes in our study population. This 
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reiterates the fact that genomic diversity varies is seen with different 
geographical location and with different seasons(11). 
 Sarkar et al in the year 2015 studied the burden of diarrhoea in the 
community and in the hospital where the prevalence of rotavirus infection was 
found to be 18% which is also comparable to our study(12). 
 A systematic review of about 54 studies on the epidemiology of rotavirus 
diarrhoea in India done by Ashok kumar et al published in the Indian journal of 
Pediatrics showed a stool positivity rate that varied from 4.6% in Kolkata to 
89.8% in Manipur among hospitalized children. The major causes were due to 
G1, G2 and untypable strains with regional variations. The infection rate varied 
from 4% in Delhi to 33.7% in Manipur in the community. The most common 
cause of nosocomial diarrhoea was found to be rotavirus with prevalence 
ranging from 5.2% to 80.5%(13)   
 Similar to studies conducted previously in varied geographical areas our 
study has shown a prevalence rate of rotaviral diarrhoea of 32%. Also the 
comparison of infection rates between vaccinated and unvaccinated children 
showed a P value of 0.035 which is statistically significant. This points to the 
fact that the 116E vaccine is effective in preventing rotaviral diarrhoea. The 
common genotypes found were G3P8, G3+G12 P8, G1P8. These are the 
prevailing strains in our community in the current season.  
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 Regarding intussusception, 10 cases were analysed. Of which 4 cases had 
received vaccine (2 partial & 2 complete). The mean duration between the date 
of 1 st dose of vaccine and onset of symptoms was 42 days. But none of the 
vaccinated children had rotaviral antigen in the stool. Among the unvaccinated 
group, 1 child had rotaviral antigen in stool. The genotype was found to be 
G1P8 different from the vaccine strain (116E –G9P10). 
 Also a comparison was done retrospectively between the admission rates 
of intussusception before the introduction of vaccine over a one year period – 
47 to that post introduction of vaccine – 10. This shows that the introduction of 
vaccine hasn’t caused an increase in the no. of intussusception cases. So the 
116E vaccine can be considered to be a relatively safe vaccine. 
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LIMITATIONS 
The sample size is small when compared to the burden of acute diarrhoea 
in the community 
 Burden of the illness in the community could not be studied 
 A proper control group could not be established due to the recent 
introduction of vaccine 
 Safety of the vaccine with regard to intussusception cant be commented 
upon based on this study as the intussusception surveillance was conducted only 
on the intussusception cases admitted to our hospital and was not done on all 
vaccinated children. This proves no causal association between the vaccine and 
the onset of intussusception. 
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CONCLUSION 
 Rotavirus is the major infectious pathogen causing acute diarrhoea in our 
hospital setting. The common age group involved was children < 1 year of age. 
There is no gender predilection. Mild illness with no dehydration and some 
dehydration formed the vast majority of the affected children. The burden of 
rotavirus diarrhoea was found to be 32% in our hospital setting. The common 
infecting genotype is G3 P8 followed by G1P8, G3+G12P8 in our geographical 
location. There was a statistical significance in the incidence of diarrhoea 
between the vaccinated and unvaccinated group. This proves that the 116E 
rotavirus vaccine is effective in reducing the occurrence of rotaviral diarrhoea.  
Larger studies are necessary to assess the safety of this vaccine. 
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RECOMMENDATION 
 This study proves that rotavirus vaccine is effective in preventing 
rotaviral diarrhoea. This makes it necessary that the vaccine should be 
introduced in all states of India. It is likely to reduce the morbidity, mortality 
and burden on our health care system. Larger studies regarding the safety of the 
vaccine with respect to intussusception is necessary as previous data regarding 
the safety of this vaccine is unavailable and insufficient.  
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PROFORMA: 
ROTAVIRUS VACCINE IMPACT ASSESSMENT: 
Name: 
Age in months: 
Sex: 
Hospital id: 
Date of admission: 
Treated at casualty/ward: 
Diagnosis: 
Weight: 
Height: 
MAC: 
Date of symptom onset: 
Duration of diarrhoea: 
No of episodes/day: 
 Vomiting yes/no: 
If yes, duration of vomiting: 
 
 
No of episodes/day: 
Fever yes/no: 
Urine output: 
Examination: 
Sensorium: 
Sunken eyes: 
Skin turgor: 
Thirst: 
Treatment details: ORT/IV fluids 
Rotavirus vaccine given/not: 
Date of vaccination: 
Stool sample collected: 
Outcome: 
Date of discharge: 
 
 
 
 
 
INTUSSUSCEPTION SURVEILLANCE: 
Name: 
Age in months: 
Sex: 
Hospital ID: 
Date of admission: 
Address: 
Weight 
Height: 
MAC: 
Date of symptom onset: 
Fever yes/no: 
Bloody stools yes/no: 
Vomiting yes/no: 
Diarrhoes yes/no: 
Abdominal pain yes/no: 
Constipation yes/no: 
 
 
USG findings: 
Treatment : spontaneous resolution/ pneumatic reduction/ surgery 
Outcome: 
Date of discharge: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABBREVIATIONS USED 
 
AGE – acute gastroenteritis 
VP – viral protein 
NSP – non structural protein 
WBC -  whole blood count 
RNA – Ribo nucleic acid 
UIP – Universal Immunisation Programme 
WHO – World Health Organisation 
ORS – Oral Rehydration Solution 
ORT-Oral Rehydration Therapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sl.No treated Age sex final_diagnosis Duration
rotavirus  
1dose
rotavirus 2 
dose
rotavirus 3 
dose outcome Stool ELISA G type P type
1 1 15 F AGE WITH SOME DEHYDRATION 2 2 2 2 1 NEG
2 1 29 M AGE WITH SOME DEHYDRATION 2 2 2 2 1 NEG
3 2 5 M AGE WITH NO DEHYDRATION 3 1 1 1 1 NEG
4 2 15 M AGE WITH NO DEHYDRATION 1 2 2 2 1 NEG
5 1 2 M AGE WITH SOME DEHYDRATION 1 1 2 2 1 POS G3 P8
6 2 38 F AGE NO DEHYDRATION 2 2 2 2 1 NEG
7 1 5 M AGE WTH NO DEHYDRATION 4 1 1 2 1 NEG
8 1 8 M AGE WITH NO DEHYDRATION 3 2 2 2 1 NEG
9 1 1 F AGE WITH SOME DEHYDRATION 6 2 2 2 1 NEG
10 1 1 F AGE WITH SOME DEHYDRATION 4 2 2 2 1 NEG
11 2 5 M AGE WITH NO DEHYDRATION 5 1 1 1 1 NEG
12 1 12 M AGE WITH NO DEHYDRATION 2 2 2 2 1 NEG
13 1 13 M AGE WITH SEVERE DEHYDRATION 5 2 2 2 1 POS G3+G9 P8
14 2 12 M AGE WITH NO DEHYDRATION 2 2 2 2 1 POS G1 P8
15 2 5 F AGE WITH NO DEHYARATION 1 1 2 2 1 NEG
16 2 11 M AGE WITH NO DEHYDRATION 1 2 2 2 1 POS G3 P8
17 2 6 M AGE WITH NOI DEHYDRATION 3 1 1 2 1 NEG
18 1 3 M AGE WITH SOME DEHYDRATION 1 2 2 2 1 NEG
19 2 5 M AGE WITH NO DEHYDRATION 1 1 2 2 1 POS G3 P8
20 2 27 F AGE WITH NO DEHYDRATION 3 2 2 2 1 NEG
21 1 7 M AGE WITH NO DEHYDRATION 4 2 2 2 1 NEG
22 2 11 M AGE WITH SOME DEHYDRATION 1 2 2 2 1 POS G3 P8
23 1 15 M AGE WITH SOME DEHYDRATION 2 2 2 2 1 POS G1 P8
24 1 11 F AGE WITH SOME DEHYDRATION 1 2 2 2 1 NEG
25 2 8 M AGE WITH NO DEHYDRATION 2 2 2 2 1 POS G1 P8
26 2 12 M AGE WITH NO DEHYDRATION 2 2 2 2 1 POS G3+G12 P8
27 2 8 F AGE WITH NO DEHYDRATION 2 1 1 2 1 NEG
28 1 6 F AGE WITH NO DEHYDRATION 1 1 1 2 1 POS G1 P8
29 2 15 F AGE WITH NO DEHYDRATION 1 1 1 1 1 POS G3+G12 P8
30 2 6 M AGE WITH NO DEHYDRATION 2 2 2 2 1 POS G3 P8
31 2 5 M AGE WITH NO DEHYDRATION 2 2 2 2 1 POS G12 P8
32 2 11 M AGE WITH NO DEHYDRATION 1 2 2 2 1 POS G1 P8
33 1 12 F AGE WITH SOME DEHYDRATION 3 2 2 2 1 NEG
34 1 10 F AGE WITH SOME DEHYDRATION 1 2 2 2 1 POS G3+G12 P8
35 1 5 F AGE WITH NO DEHYDRATION 3 2 2 2 1 NEG
36 1 5 F AGE WITH NO DEHYDRATION 3 2 2 2 1 NEG
37 2 7 F AGE WITH NO DEHYDRATION 2 2 2 2 1 NEG
38 1 8 M AGE WITH SOME DEHYDRATION 3 2 2 2 1 NEG
39 1 6 M AGE WITH NO DEHYDRATION 3 1 1 1 1 NEG
40 1 20 M AGE WITH NO DEHYDRATION 2 2 2 2 1 POS G3 P8
41 2 22 M AGE WITH NO DEHYDRATION 1 2 2 2 1 POS G12 P8
42 2 13 M AGE WITH NO DEHYDRATION 2 2 2 2 1 NEG
43 1 9 F AGE WITH SOME DEHYDRATION 1 2 2 2 1 POS G3 P8
44 2 6 M AGE WITH NO DEHYDRATION 2 2 2 2 1 NEG
45 2 26 F AGE WITH NO DEHYDRATION 2 2 2 2 1 NEG
46 1 8 M AGE WITH NO DEHYDRATION 1 2 2 2 1 POS G1 P6
47 1 5 M AGE WITH FEVER 1 1 1 1 1 NEG
48 1 9 F AGE WITH SEVERE DEHYDRATION 1 2 2 2 1 NEG
49 1 6 M AGE WITH NO DEHYDRATION 1 1 1 1 1 POS G3+G12 P8
50 1 6 F AGE WITH NO DEHYDRATION 1 1 1 1 1 POS G12 P8
51 1 6 M AGE WITH SOME DEHYDRATION 1 1 1 1 1 POS G12 P8
52 2 6 M AGE WITH NO DEHYDRATION 2 2 2 2 1 NEG
53 2 11 F AGE WITH NO DEHYDRATION 2 2 2 2 1 NEG
54 1 2 F AGE WITH SOME DEHYDRATION 1 1 2 2 1 POS G12 P8
55 2 11 M AGE WITH NO DEHYDRATION 1 2 2 2 1 NEG
56 1 12 M AGE WITH SOME DEHYDRATION 1 2 2 2 1 NEG
57 1 10 F AGE WITH SOME DEHYDRATION 1 2 2 2 1 POS G12+G3 P8
58 1 8 F AGE WITH SOME DEHYDRATION 1 2 2 2 1 POS G3 P8
59 2 20 M AGE WITH NO DEHYDRATION 1 2 2 2 1 POS G3 P8
60 2 7 F AGE WITH NO DEHYDRATION 2 1 1 1 1 NEG
61 2 24 M AGE WITH NO DEHYDRATION 1 2 2 2 1 NEG
62 2 38 F AGE WITH NO DEHYDRATION 1 2 2 2 1 POS G3 P8
63 1 6 F AGE WITH SEVERE DEHYDRATION 1 1 2 2 1 POS G1 P8
64 1 11 F AGE WITH SEVERE DEHYDRATION 1 2 2 2 1 POS G3 P8
65 2 16 F AGE WITH NO DEHYDRATION 3 2 2 2 1 POS G3 P8
66 1 13 F AGE WITH SEVERE DEHYDRATION 2 2 2 2 1 NEG
67 1 7 M AGE WITH SOME DEHYDRATION 3 2 2 2 1 POS G3 P8
68 2 18 M AGE WITH NO DEHYDRATION 4 2 2 2 1 POS G3 P8
69 1 10 F AGE WITH SOME DEHYDRATION 4 2 2 2 1 NEG
70 1 18 F AGE WITH SOME DEHYDRATION 2 2 2 2 1 POS G1 P8
71 2 19 M AGE WITH NO DEHYDRATION 1 2 2 2 1 NEG
72 2 16 M AGE WITH NO DEHYDRATION 2 2 2 2 1 NEG
73 1 11 M AGE WITH SOME DEHYDRATION 1 2 2 2 1 POS G1 P8
74 1 14 M AGE WITH SOME DEHYDRATION 1 2 2 2 1 POS G3 P8
75 1 9 M AGE WITH NO DEHYDRATION 1 2 2 2 1 NEG
76 2 16 F AGE WITH NO DEHYDRATION 2 2 2 2 1 POS G3 P8
77 1 29 F AGE WITH SOME DEHYDRATION 1 2 2 2 1 POS G3 P8
78 1 16 F AGE WITH SOME DEHYDRATION 2 2 2 2 1 NEG
79 1 10 M AGE WITH SOME DEHYDRATION 4 2 2 2 1 POS G3 P8
80 1 17 M AGE WITH NO DEHYDRATION 1 2 2 2 1 POS G3 P8
81 1 7 F AGE WITH NO DEHYDRATION 1 2 2 2 1 NEG
82 1 17 F AGE WITH NO DEHYDRATION 1 2 2 2 1 POS G3+G12 P8
83 2 5 F AGE WITH NO DEHYDRATION 1 1 2 2 1 NEG
84 1 19 F AGE WITH SOME DEHYDRATION 2 2 2 2 1 POS G3 P8
85 2 21 F AGE WITH NO DEHYDRATION 1 1 1 1 1 POS G3 P8
86 2 4 M AGE WITH NO DEHYDRATION 1 2 2 2 1 NEG
87 1 3 F AGE WITH SOME DEHYDRATION 1 1 2 2 1 POS G3 P8
88 1 30 M AGE WITH NO DEHYDRATION 1 2 2 2 1 POS G3 P8
89 1 8 M AGE WITH SOME DEHYDRATION 1 2 2 2 1 NEG
90 2 8 F AGE WITH NO DEHYDRATION 1 2 2 2 1 NEG
91 1 11 F AGE WITH SOME DEHYDRATION 1 2 2 2 1 POS G3+G12 P8
92 1 11 M AGE WITH SEVERE DEHYDRATION 1 2 2 2 1 NEG
93 1 14 F AGE WITH SOME DEHYDRATION 6 2 2 2 1 NEG
94 1 1 M AGE WITH SOME DEHYDRATION 1 2 2 2 1 NEG
95 2 12 M AGE WITH NO DEHYDRATION 2 2 2 2 1 POS G3+G10 P8
96 1 5 F AGE WITH NO DEHYDRATION 1 2 2 2 1 NEG
97 2 43 F AGE WITH NO DEHYDRATION 2 2 2 2 1 NEG
98 1 26 F AGE WITH SOME DEHYDRATION 2 1 1 2 1 NEG
99 2 12 M AGE WITH SOME DEHYDRATION 1 1 1 1 1 POS G3+G12 P8
100 2 1 M AGE WITH NO DEHYDRATION 1 2 2 2 1 NEG
101 2 1 F AGE WITH NO DEHYDRATION 1 2 2 2 1 NEG
102 2 2 M AGE WITH NO DEHYDRATION 2 1 2 2 1 NEG
103 2 6 F AGE WITH NO DEHYDRATION 2 2 2 2 1 NEG
104 1 1 M AGE WITH SOME DEHYDRATION 3 2 2 2 1 NEG
105 2 6 F AGE WITH NO DEHYDRATION 3 1 1 1 1 NEG
106 1 16 M AGE WITH SEVERE DEHYDRATION 2 2 2 2 1 POS G3+G10 P8
107 2 34 M AGE WITH NO DEHYDRATION 2 2 2 2 1 NEG
108 2 11 M AGE WITH NO DEHYDRATION 1 2 2 2 1 NEG
109 2 6 F AGE WITH NO DEHYDRATION 1 2 2 2 1 NEG
110 1 9 F AGE WITH SOME DEHYDRATION 1 2 2 2 1 NEG
111 1 41 M AGE WITH SOME DEHYDRATION 1 2 2 2 1 NEG
112 1 10 F AGE WITH SEVERE DEHYDRATION 2 2 2 2 1 NEG
113 1 17 M AGE WITH SOME DEHYDRATION 2 2 2 2 1 POS G3+G12 P8
114 2 3 M AGE WITH NO DEHYDRATION 1 1 2 2 1 NEG
115 2 5 F AGE WITH NO DEHYDRATION 2 1 1 2 1 NEG
116 2 5 M AGE WITH NO DEHYDRATION 3 1 1 1 1 NEG
117 1 11 F AGE WITH SOME DEHYDRATION 5 2 2 2 1 NEG
118 1 5 F AGE WITH SOME DEHYDRATION 2 2 2 2 1 NEG
119 1 5 M AGE WITH SOME DEHYDRATION 1 2 2 2 1 NEG
120 1 24 M AGE WITH SOME DEHYDRATION 3 2 2 2 1 NEG
121 2 4 M AGE WITH NO DEHYDRATION 1 1 1 1 1 NEG
122 2 10 M AGE WITH NO DEHYDRATION 1 2 2 2 1 NEG
123 1 10 M AGE WITH SOME DEHYDRATION 1 2 2 2 1 POS G3 P8
124 1 10 M AGE WITH SOME DEHYDRATION FEVER 1 2 2 2 1 NEG
125 1 14 M AGE WITH SEVERE DEHYDRATION 5 2 2 2 1 NEG
126 1 8 M AGE WITH NO DEHYDRATION 2 1 2 2 1 NEG
127 1 7 F AGE WITH SOME DEHYDRATION 1 2 2 2 1 POS G1 P6
128 2 3 M AGE WITH NO DEHYDRATION 1 1 1 2 1 NEG
129 2 8 F AGE WITH NO DEHYDRATION 1 1 2 2 1 NEG
130 1 5 F AGE WITH NO DEHYDRATION 1 1 1 2 1 NEG
131 2 9 M AGE WITH SEVERE DEHYDRATION 3 2 2 2 1 POS
132 2 5 M AGE WITH NO DEHYDRATION 1 1 1 1 1 NEG
133 1 12 F AGE WITH SEVERE DEHYDRATION 2 2 2 2 1 POS G3 P6+P8
134 2 2 M AGE WITH NO DEHYDRATION 1 1 2 2 1 NEG
135 2 5 F AGE WITH NO DEHYDRATION 3 1 1 1 1 NEG
136 1 6 M AGE WITH NO DEHYDRATION 2 1 1 1 1 NEG
137 1 5 M AGE WITH NO DEHYDRATION 1 1 1 1 1 NEG
138 1 6 M AGE WITH SOME DEHYDRATION 4 1 1 1 1 NEG
139 1 8 F AGE WITH SOME DEHYDRATION 1 2 2 2 1 POS G3 P4
140 2 8 M AGE WITH NO DEHYDRATION 1 1 1 1 1 NEG
141 1 9 M AGE WITH SOME DEHYDRATION 3 1 1 1 1 NEG
142 1 8 M AGE WITH NO DEHYDRATION 1 1 1 1 1 NEG
143 2 4 M AGE WITH NO DEHYDRATION 1 1 1 1 1 NEG
144 2 2 F AGE WITH NO DEHYDRATION 1 1 1 2 1 NEG
145 1 3 M AGE WITH NO DEHYDRATION 2 1 1 2 1 NEG
146 1 24 M AGE WITH SOME DEHYDRATION 3 2 2 2 1 POS G3+G10 P8
147 1 3 M AGE WITH SOME DEHYDRATION 1 1 2 2 1 NEG
148 2 4 F AGE WITH NO DEHYDRATION 1 1 1 1 1 NEG
149 1 9 M AGE WITH SOME DEHYDRATION 1 1 1 1 1 NEG
150 1 5 M AGE WITH SOME DEHYDRATION 2 1 1 1 1 NEG
151 2 8 M AGE WITH NO DEHYDRATION 2 1 1 1 1 NEG
152 1 5 M AGE WITH NO DEHYDRATION 2 1 1 1 1 NEG
153 1 5 M AGE WITH NO DEHYDRATION 1 1 1 1 1 NEG
154 2 9 M AGE WITH NO DEHYDRATION 1 1 1 1 1 NEG
155 1 7 M AGE WITH NO DEHYDRATION 1 1 1 1 1 NEG
156 1 2 M AGE WITH NO DEHYDRATION 2 1 2 2 1 NEG
157 2 1 M AGE WITH NO DEHYDRATION 3 1 2 2 1 NEG
158 1 23 M AGE WITH SOME DEHYDRATION 1 2 2 2 1 POS G9 P4
159 1 8 F AGE WITH NO DEHYDRATION 2 1 1 1 1 NEG
160 1 5 F AGE WITH SOME DEHYDRATION 1 1 1 1 1 NEG
161 1 19 M AGE WITH SOME DEHYDRATION 3 2 2 2 1 POS G3 P8
162 1 2 F AGE WITH NO DEHYDRATION 1 1 2 2 1 NEG
163 1 2 M AGE WITH NO DEHYDRATION 1 1 2 2 1 NEG
164 1 2 F AGE WITH SEVERE DEHYDRATION 1 1 2 2 1 NEG
165 1 9 F AGE WITH SOME DEHYDRATION 6 1 1 2 1 NEG
166 1 4 M AGE WITH NO DEHYDRATION 1 1 1 1 1 NEG
167 1 10 M AGE WITH NO DEHYDRATION 2 1 1 1 1 NEG
168 1 5 M AGE WITH SOME DEHYDRATION 2 1 1 1 1 NEG
169 2 6 M AGE WITH NO DEHYDRATION 1 1 1 1 1 NEG
170 2 48 F AGE WITH NO DEHYDRATION 2 2 2 2 1 POS UT
171 1 4 F AGE WITH SOME DEHYDRATION 1 1 1 2 1 NEG
172 1 8 F AGE WITH NO DEHYDRATION 3 1 1 1 1 NEG
173 1 8 M AGE WITH SOME DEHYDRATION 2 1 1 1 1 NEG
174 1 10 F AGE WITH NO DEHYDRATION 1 1 1 1 1 NEG
175 1 8 F AGE WITH NO DEHYDRATION 1 1 1 1 1 NEG
176 1 2 F AGE WITH SOME DEHYDRATION 1 1 2 2 1 NEG
177 1 6 M AGE WITH SEVERE DEHYDRATION 2 1 1 2 1 NEG
178 1 10 F AGE WITH SOME DEHYDRATION 1 1 1 1 1 NEG
179 1 7 M AGE WITH NO DEHYDRATION 1 1 1 1 1 NEG
180 1 6 F AGE WITH NO DEHYDRATION 1 1 1 1 1 NEG
ROTAVIRUS 
VACCINE
NO OF DOSES 
RECEIVED DURATION BETWEEN ROTA RESULT
VACCINE & ONSET OF SYMPTOMS RESULTS G TYPE P TYPE
ISTN190001 SRI SANTOSH KUMAR 107240 02 MALE YES 1 5DAYS NEG
ISTN190002 B/O PREMA 2666 03 FEMALE YES 2 16DAYS NEG
ISTN190003 NAVEEN KUMAR 3067 04 MALE NO 0 0 NEG
ISTN190004 DHARSHAN 3310 05 MALE YES 3 2 MONTHS NEG
ISTN190005 DEEKSHANA 6825 18 FEMALE NO 0 0 NEG
ISTN190006 ASWATH GURU 13289 07 MALE NO 0 0 NEG
ISTN190007 SIVANAYA SHREE 18653 06 FEMALE YES 3 3 MONTHS NEG
ISTN190008 SIVARANJANI 36409 06 FEMALE NO 0 0 POS G1 P8
ISTN190009 GOKULA VARSHAN 36816 11 MALE NO 0 0 NEG
ISTN190010 DHARSHAN 38301 12 MALE NO 0 0 NEG
REMARKSRVIS NO CHILD NAME IP NO AGE SEX
GENO TYPING
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